Bo Wen
Research Subjects
Bo Wen has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Daoyuan Ding
Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, 518104, Guangdong, China
3 shared publicationsHuajie Zhang
Department of Urology, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, China
2 shared publicationsJiangtao Li
Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, 518104, Guangdong, China
2 shared publicationsJihong Liu
Department of Urology, Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications- Ke Rao
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2 shared publications Qi Liu
Department of Urology, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, China
2 shared publications
Latest Publications
- 3 November 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt B) , 120601
Correspondence to the Editor: Comment on “The impact of anxiety on the risk of kidney stone disease: Insights into eGFR-mediated effects”
- 3 November 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt B) , 120601
Correspondence to the Editor: Comment on “The impact of anxiety on the risk of kidney stone disease: Insights into eGFR-mediated effects”
- Open Access
- 14 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-14
Integrated bioinformatics and machine learning reveal key genes and immune mechanisms associated with uremia
Uremia is a serious complication of end-stage chronic kidney disease, closely associated with immune imbalance and chronic inflammation. However, its molecular mechanisms remain largely unclear. In this study, we analyzed transcriptomic data from the GSE37171 dataset to identify genes associated with uremia. Differential expression and WGCNA analyses were used to screen core genes, followed by machine learning (LASSO, Random Forest, SVM-RFE) to identify key feature genes. GSEA and immune infiltration analyses were conducted to explore functional pathways and immune relevance. ROC curves were used to evaluate the discriminatory power of the selected genes. Four feature genes—NAF1, SNORD4A, CGB3, and CD3E—were identified. These genes were enriched in pathways related to apoptosis, immune regulation, and oxidative stress. Their expression levels correlated with multiple immune cell types, and ROC analysis demonstrated good discriminatory performance between uremia and healthy samples. Our findings provide potential molecular candidates for further investigation into the immune-related mechanisms of uremia.
- 14 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-14
Open AccessIntegrated bioinformatics and machine learning reveal key genes and immune mechanisms associated with uremia
Uremia is a serious complication of end-stage chronic kidney disease, closely associated with immune imbalance and chronic inflammation. However, its molecular mechanisms remain largely unclear. In this study, we analyzed transcriptomic data from the GSE37171 dataset to identify genes associated with uremia. Differential expression and WGCNA analyses were used to screen core genes, followed by machine learning (LASSO, Random Forest, SVM-RFE) to identify key feature genes. GSEA and immune infiltration analyses were conducted to explore functional pathways and immune relevance. ROC curves were used to evaluate the discriminatory power of the selected genes. Four feature genes—NAF1, SNORD4A, CGB3, and CD3E—were identified. These genes were enriched in pathways related to apoptosis, immune regulation, and oxidative stress. Their expression levels correlated with multiple immune cell types, and ROC analysis demonstrated good discriminatory performance between uremia and healthy samples. Our findings provide potential molecular candidates for further investigation into the immune-related mechanisms of uremia.
- Top Cited PapersOpen Access
- 5 September 2022
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 13 (1) , 1-16
Human umbilical cord mesenchymal stem cells ameliorate erectile dysfunction in rats with diabetes mellitus through the attenuation of ferroptosis
Background: Erectile dysfunction (ED), as one of the most prevalent consequences in male diabetic patients, has a serious impact on men's physical and mental health, and the treatment effect of diabetic mellitus erectile dysfunction (DMED) is often worse. Therefore, the development of a novel therapeutic approach is urgent. As stem cells with high differentiation potential, human umbilical cord mesenchymal stem cells (HUCMSCs) have been widely used in the treatment of diseases in other systems, and are expected to be a promising strategy for the treatment of DMED. In this study, we investigated the role of HUCMSCs in managing erectile function in rat models of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) and compared the effects of two different injection methods. Methods: T1DM and T2DM ED rats were given labelled HUCMSCs by corpus cavernosum injection and tail vein injection, respectively. ICP and MAP were monitored simultaneously by electrical stimulation four weeks after injection to indicate the erectile function of rats. To track the development and colonisation capabilities of stem cells, we performed EdU assay with penile tissue. The histological changes of the penis were observed by hematoxylin–eosin staining, and Masson’s trichrome staining was conducted to evaluate the smooth muscle content and the degree of fibrosis in the rat penis. Then, we employed specific kits to measure the level of NO, cGMP, MDA, SOD and Fe in penis. Electron transmission microscopy was implemented to observe morphology of mitochondria. Besides, western blot and immunofluorescence staining were performed to demonstrate the expression of ferroptosis-related genes. Results: We found that HUCMSCs improved erectile function in T1DM and T2DM ED rats, with no difference in efficacy between corpus cavernosum injection and tail vein injection. The EdU assay revealed that only a tiny percentage of HUCMSCs colonised the corpus cavernosum, while smooth muscle in the penis expanded and collagen decreased following HUCMSC injection. Moreover, the levels of oxidative stress in the penis of the rats given HUCMSCs were dramatically reduced, as was the tissue iron content. HUCMSCs normalised mitochondrial morphology within corpus cavernosum smooth muscle cells (CCSMCs), which were characteristically altered by high glucose. Furthermore, the expression of ferroptosis inhibitory genes SLC7A11 and GPX4 was obviously elevated in CCSMCs after stem cell management, but the abundances of ACSL4, LPCAT3 and ALOX15 showed the polar opposite tendency. Conclusions: HUCMSCs can effectively and safely alleviate erectile dysfunction in T1DM and T2DM ED rats, while restoring erectile function by attenuating diabetes-induced ferroptosis in CCSMCs. Additionally, this study provides significant evidence for the development of HUCMSCs as a viable therapeutic strategy for DMED.
- 5 September 2022
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 13 (1) , 1-16
Top Cited PapersOpen AccessHuman umbilical cord mesenchymal stem cells ameliorate erectile dysfunction in rats with diabetes mellitus through the attenuation of ferroptosis
Background: Erectile dysfunction (ED), as one of the most prevalent consequences in male diabetic patients, has a serious impact on men's physical and mental health, and the treatment effect of diabetic mellitus erectile dysfunction (DMED) is often worse. Therefore, the development of a novel therapeutic approach is urgent. As stem cells with high differentiation potential, human umbilical cord mesenchymal stem cells (HUCMSCs) have been widely used in the treatment of diseases in other systems, and are expected to be a promising strategy for the treatment of DMED. In this study, we investigated the role of HUCMSCs in managing erectile function in rat models of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) and compared the effects of two different injection methods. Methods: T1DM and T2DM ED rats were given labelled HUCMSCs by corpus cavernosum injection and tail vein injection, respectively. ICP and MAP were monitored simultaneously by electrical stimulation four weeks after injection to indicate the erectile function of rats. To track the development and colonisation capabilities of stem cells, we performed EdU assay with penile tissue. The histological changes of the penis were observed by hematoxylin–eosin staining, and Masson’s trichrome staining was conducted to evaluate the smooth muscle content and the degree of fibrosis in the rat penis. Then, we employed specific kits to measure the level of NO, cGMP, MDA, SOD and Fe in penis. Electron transmission microscopy was implemented to observe morphology of mitochondria. Besides, western blot and immunofluorescence staining were performed to demonstrate the expression of ferroptosis-related genes. Results: We found that HUCMSCs improved erectile function in T1DM and T2DM ED rats, with no difference in efficacy between corpus cavernosum injection and tail vein injection. The EdU assay revealed that only a tiny percentage of HUCMSCs colonised the corpus cavernosum, while smooth muscle in the penis expanded and collagen decreased following HUCMSC injection. Moreover, the levels of oxidative stress in the penis of the rats given HUCMSCs were dramatically reduced, as was the tissue iron content. HUCMSCs normalised mitochondrial morphology within corpus cavernosum smooth muscle cells (CCSMCs), which were characteristically altered by high glucose. Furthermore, the expression of ferroptosis inhibitory genes SLC7A11 and GPX4 was obviously elevated in CCSMCs after stem cell management, but the abundances of ACSL4, LPCAT3 and ALOX15 showed the polar opposite tendency. Conclusions: HUCMSCs can effectively and safely alleviate erectile dysfunction in T1DM and T2DM ED rats, while restoring erectile function by attenuating diabetes-induced ferroptosis in CCSMCs. Additionally, this study provides significant evidence for the development of HUCMSCs as a viable therapeutic strategy for DMED.
- Open Access
- 29 March 2021
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 8
Up-Regulating ERIC by CRISPR-dCas9-VPR Inhibits Cell Proliferation and Invasion and Promotes Apoptosis in Human Bladder Cancer
LncRNAs are defined as non-coding RNAs that are longer than 200 nucleotides in length. The previous studys has shown that lncRNAs played important roles in the regulation of gene expression and were essential in mammalian development and disease processes. Inspired by the observation that lncRNAs are aberrantly expressed in tumors, we extracted RNA from Bladder urothelial carcinoma and matched histologically normal urothelium from each patient and bladder carcinoma cell lines. Then, we reversed transcribed them into cDNA.Last, we investigated the expression patterns of ERIC by the fluorescence quantitative PCR in bladder cancer tissues and cell lines. CRISPR-dCas9-VPR targeting ERIC plasmid was transfected into T24 and 5637 cells, and cells were classified into two groups: negative control (NC) and ERIC overexpression group. MTT assay, transwell assay, and flow cytometry were performed to examine changes in cell proliferation, invasiveness, and apoptosis. We found that the expression of ERIC was down-regulated in bladder urothelial carcinoma compared to matched histologically normal urotheliam. The differences of the expression of this gene were large in the bladder cancer lines. Compared with the negative control group, the ERIC overexpression group showed significantly decreased cell proliferation rate (t = 7.583, p = 0.002; t = 3.283, p = 0.03) and invasiveness (t = 11.538, p < 0.001; t = 8.205, p = 0.01); and increased apoptotic rate (t = −34.083, p < 0.001; t = −14.316, p < 0.001). Our study lays a foundation for further study of its pathogenic mechanism in bladder cancer.
- 29 March 2021
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 8
Open AccessUp-Regulating ERIC by CRISPR-dCas9-VPR Inhibits Cell Proliferation and Invasion and Promotes Apoptosis in Human Bladder Cancer
LncRNAs are defined as non-coding RNAs that are longer than 200 nucleotides in length. The previous studys has shown that lncRNAs played important roles in the regulation of gene expression and were essential in mammalian development and disease processes. Inspired by the observation that lncRNAs are aberrantly expressed in tumors, we extracted RNA from Bladder urothelial carcinoma and matched histologically normal urothelium from each patient and bladder carcinoma cell lines. Then, we reversed transcribed them into cDNA.Last, we investigated the expression patterns of ERIC by the fluorescence quantitative PCR in bladder cancer tissues and cell lines. CRISPR-dCas9-VPR targeting ERIC plasmid was transfected into T24 and 5637 cells, and cells were classified into two groups: negative control (NC) and ERIC overexpression group. MTT assay, transwell assay, and flow cytometry were performed to examine changes in cell proliferation, invasiveness, and apoptosis. We found that the expression of ERIC was down-regulated in bladder urothelial carcinoma compared to matched histologically normal urotheliam. The differences of the expression of this gene were large in the bladder cancer lines. Compared with the negative control group, the ERIC overexpression group showed significantly decreased cell proliferation rate (t = 7.583, p = 0.002; t = 3.283, p = 0.03) and invasiveness (t = 11.538, p < 0.001; t = 8.205, p = 0.01); and increased apoptotic rate (t = −34.083, p < 0.001; t = −14.316, p < 0.001). Our study lays a foundation for further study of its pathogenic mechanism in bladder cancer.
JTE‐013 supplementation improves erectile dysfunction in rats with streptozotocin‐induced type Ⅰ diabetes through the inhibition of the rho‐kinase pathway, fibrosis, and apoptosis
Background: Erectile dysfunction (ED) is a common complication in patients with diabetes mellitus (DM) that severely affects the patients' quality of life. However, the effectiveness of oral phosphodiesterase type 5 inhibitors in these patients is poor. Sphingosine‐1‐phosphate (S1P) and S1P receptor 2 (S1PR2) are important factors regulating the Rho‑kinase pathway, and understanding these factors may provide ideas for new therapeutic strategies for ED.Objectives: To investigate whether the S1PR2 receptor antagonist JTE‐013 could improve DM‐induced ED (DMED) in rats and to explore the potential mechanisms.Materials and methods: We used 50 male Sprague Dawley rats (8 weeks old) for this experiment. Type Ⅰ DM was induced in forty‐two rats via streptozotocin administration; the rest of the rats served as controls. Eight weeks after DM induction, rats with ED were selected via an apomorphine test. Eight of them were injected intraperitoneally with JTE‐013 each day for 4 weeks. The rest were fed under the same conditions for 4 weeks. Erectile function was measured by cavernous nerve electrostimulation. The expression levels of related signaling pathways were evaluated using Western blotting, real‐time PCR, and immunohistochemistry.Results: Erectile function was significantly impaired in the DMED group compared with the control group and was partially improved in the DMED + JTE‐013 group. The expression of S1PR2 and the activity of the RhoA/ROCK/phospho‐myosin phosphatase target subunit 1 (p‐MYPT1) pathway proteins were higher in the DMED group than in the other two groups, and JTE‐013 treatment significantly reduced the expression/activity of these proteins. Furthermore, the DMED group showed severe corporal fibrosis, a higher apoptotic index and increased activity in the TGF‐β1/LIMK2/Cofilin pathway compared with the control group. JTE‐013 supplementation significantly ameliorated these pathological changes.Discussion and conclusion: JTE‐013 supplementation partially improved erectile function in rats with DMED, likely by inhibiting smooth muscle contraction, corporal fibrosis, and apoptosis.
JTE‐013 supplementation improves erectile dysfunction in rats with streptozotocin‐induced type Ⅰ diabetes through the inhibition of the rho‐kinase pathway, fibrosis, and apoptosis
Background: Erectile dysfunction (ED) is a common complication in patients with diabetes mellitus (DM) that severely affects the patients' quality of life. However, the effectiveness of oral phosphodiesterase type 5 inhibitors in these patients is poor. Sphingosine‐1‐phosphate (S1P) and S1P receptor 2 (S1PR2) are important factors regulating the Rho‑kinase pathway, and understanding these factors may provide ideas for new therapeutic strategies for ED.Objectives: To investigate whether the S1PR2 receptor antagonist JTE‐013 could improve DM‐induced ED (DMED) in rats and to explore the potential mechanisms.Materials and methods: We used 50 male Sprague Dawley rats (8 weeks old) for this experiment. Type Ⅰ DM was induced in forty‐two rats via streptozotocin administration; the rest of the rats served as controls. Eight weeks after DM induction, rats with ED were selected via an apomorphine test. Eight of them were injected intraperitoneally with JTE‐013 each day for 4 weeks. The rest were fed under the same conditions for 4 weeks. Erectile function was measured by cavernous nerve electrostimulation. The expression levels of related signaling pathways were evaluated using Western blotting, real‐time PCR, and immunohistochemistry.Results: Erectile function was significantly impaired in the DMED group compared with the control group and was partially improved in the DMED + JTE‐013 group. The expression of S1PR2 and the activity of the RhoA/ROCK/phospho‐myosin phosphatase target subunit 1 (p‐MYPT1) pathway proteins were higher in the DMED group than in the other two groups, and JTE‐013 treatment significantly reduced the expression/activity of these proteins. Furthermore, the DMED group showed severe corporal fibrosis, a higher apoptotic index and increased activity in the TGF‐β1/LIMK2/Cofilin pathway compared with the control group. JTE‐013 supplementation significantly ameliorated these pathological changes.Discussion and conclusion: JTE‐013 supplementation partially improved erectile function in rats with DMED, likely by inhibiting smooth muscle contraction, corporal fibrosis, and apoptosis.
- 13 September 2016
- Published by Wiley in Andrologia
- Vol. 49 (7) , e12693
Hyperlipidemia impairs erectile function in rats by causing cavernosal fibrosis
Men with hyperlipidemia are more likely to have erectile dysfunction (ED) than those without hyperlipidemia, but the mechanisms are not fully understood. The aim of this study was to investigate the underlying mechanism of ED caused by hyperlipidemia. Fourteen 8‐week‐old Sprague–Dawley rats were randomly divided into two groups: a control group and a hyperlipidemia group (fed chow containing 4% cholesterol and 1% cholic acid). After 6 months, we assessed erectile function by performing cavernous nerve electrostimulation followed by intracavernosal pressure/mean arterial pressure measurements, as well as plasma lipid profile assessment in all rats. A transferase‐mediated nick end labeling (TUNEL) assay, immunohistochemical staining and Western blotting were performed to determine the levels of apoptosis, autophagy and fibrosis in the penile tissue. Compared with the control group, the hyperlipidemia group exhibited: (i) increased plasma lipid levels; (ii) decreased erectile function; (iii) a decreased smooth muscle/collagen ratio; (iv) increased fibrosis; (v) increased apoptosis and decreased autophagy. Overall, hyperlipidemia may attenuate erectile function in rats by causing of cavernosal fibrosis.
- 13 September 2016
- Published by Wiley in Andrologia
- Vol. 49 (7) , e12693
Hyperlipidemia impairs erectile function in rats by causing cavernosal fibrosis
Men with hyperlipidemia are more likely to have erectile dysfunction (ED) than those without hyperlipidemia, but the mechanisms are not fully understood. The aim of this study was to investigate the underlying mechanism of ED caused by hyperlipidemia. Fourteen 8‐week‐old Sprague–Dawley rats were randomly divided into two groups: a control group and a hyperlipidemia group (fed chow containing 4% cholesterol and 1% cholic acid). After 6 months, we assessed erectile function by performing cavernous nerve electrostimulation followed by intracavernosal pressure/mean arterial pressure measurements, as well as plasma lipid profile assessment in all rats. A transferase‐mediated nick end labeling (TUNEL) assay, immunohistochemical staining and Western blotting were performed to determine the levels of apoptosis, autophagy and fibrosis in the penile tissue. Compared with the control group, the hyperlipidemia group exhibited: (i) increased plasma lipid levels; (ii) decreased erectile function; (iii) a decreased smooth muscle/collagen ratio; (iv) increased fibrosis; (v) increased apoptosis and decreased autophagy. Overall, hyperlipidemia may attenuate erectile function in rats by causing of cavernosal fibrosis.
- 1 July 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 463 (3) , 458-465
TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis
- 1 July 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 463 (3) , 458-465
TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis
- 1 December 2006
- Published by Springer Nature in The Chinese-German Journal of Clinical Oncology
- Vol. 5 (6) , 438-441
Experimental study on the invasiveness inhibition of bladder cancer cells by nuclear factor-κB decoy—circular dumbbell oligodeoxynucleotides
- 1 December 2006
- Published by Springer Nature in The Chinese-German Journal of Clinical Oncology
- Vol. 5 (6) , 438-441
Experimental study on the invasiveness inhibition of bladder cancer cells by nuclear factor-κB decoy—circular dumbbell oligodeoxynucleotides